{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T11:40:40Z","timestamp":1771587640934,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Herrick Foundation"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30CA022453"],"award-info":[{"award-number":["P30CA022453"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jns.2018.06.024","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T13:48:04Z","timestamp":1530539284000},"page":"100-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6781-252X","authenticated-orcid":false,"given":"Aaron","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shitiz","family":"Sriwastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirish M.","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Lisak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.jns.2018.06.024_bb0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jneuroim.2012.05.011","article-title":"Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine","volume":"250","author":"Poulas","year":"2012","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.jns.2018.06.024_bb0010","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr. Opin. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2018.06.024_bb0015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF00314173","article-title":"Thymectomy in the treatment of myasthenia gravis: report of 247 patients","volume":"235","author":"Evoli","year":"1988","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2018.06.024_bb0020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mus.21528","article-title":"Coexistent autoimmune autonomic ganglionopathy and myasthenia gravis associated with non-small-cell lung cancer","volume":"41","author":"Peltier","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2018.06.024_bb0025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.molmed.2010.02.001","article-title":"Antitumor and immune-adjuvant activities of protein-tyrosine kinase inhibitors","volume":"16","author":"Seliger","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jns.2018.06.024_bb0030","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/725410","article-title":"Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment","volume":"2013","author":"Ahmadieh","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jns.2018.06.024_bb0035","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJM196612152752401","article-title":"Antibodies to muscle and thymus in nonmyasthenic patients. Clinical evaluation","volume":"275","author":"McFarlin","year":"1966","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jns.2018.06.024_bb0040","first-page":"585","article-title":"Striational antibodies in a paraneoplastic context","volume":"47","author":"Mckeon","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.06.024_bb0045","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.pupt.2006.07.001","article-title":"Nicotinic activates cell-signaling muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells","volume":"20","author":"Carlisele","year":"2007","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.jns.2018.06.024_bb0050","doi-asserted-by":"crossref","unstructured":"Solomon, B, Shaw, A, Ou,S, Besse, B, Felip, E. Phase 2 sudy of lorlatinib in patients with advanced ALK+\/ROS1+ non-small-cell lng cancer. J. Thorac. Oncol. 2017. 12: Suppl. 2, S1756, (abstract OA 05.06).","DOI":"10.1016\/j.jtho.2017.09.351"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18302740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18302740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:45:29Z","timestamp":1758383129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18302740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":10,"alternative-id":["S0022510X18302740"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.06.024","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}